Government-Owned Inventions; Availability for Licensing, 48439 [2016-17419]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 142 / Monday, July 25, 2016 / Notices
Child Health and Human Development, NIH,
6710B Rockledge Drive, Room 2314,
Bethesda, MD 20892, (301) 496–8535,
dhann@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: July 19, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–17423 Filed 7–22–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Novel metastatic
serous epithelial ovarian cancer (SEOC)
genetically engineered mouse models,
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:27 Jul 22, 2016
Jkt 238001
cell lines, and orthotopic models based
on Rb, p53 and/or Brca 1/2 inactivation
useful for biomarker discovery and
preclinical testing.
Description of Technology: The high
mortality rate from ovarian cancers can
be attributed to late-stage diagnosis and
lack of effective treatment. Despite
enormous effort to develop better
targeted therapies, platinum-based
chemotherapy still remains the standard
of care for ovarian cancer patients, and
resistance occurs at a high rate. One of
the rate limiting factors for translation of
new drug discoveries into clinical
treatments has been the lack of suitable
preclinical cancer models with high
predictive value.
NCI CAPR has developed Tri-allelic
K18–T121 tg/∂ /Brca1 fl/fl /p53 fl/fl SEOC
GEM Model, GEM-derived SEOC
orthotopic mouse model, and biological
materials derived therefrom, with
several key histopathologic,
immunophenotypical, and genetic
features of human SEOC. SEOC GEMs
were utilized to create orthotopic
immunocompetent transplant models,
and to generate synchronized cohorts of
mice suitable for preclinical studies.
NCI CAPR conducted studies that
determine these models are tractable for
use in routine efficacy studies and
demonstrate the utility of these models
in evaluating the potential efficacy of
novel therapeutics for ovarian cancer.
Potential Commercial Applications:
• These models serve as a foundation
for preclinical research and evaluation
of efficacy of novel therapeutics for
ovarian cancer.
• The GEM models described here
can be used to develop cell lines and
allograft models for evaluating drug
potency relative to Brca1 mutation
status.
• These mouse models provide the
opportunity for evaluation of effective
therapeutics, including prediction of
differential responses in Brca1-wild
type and Brca1–deficient tumors and
development of relevant biomarkers.
Value Proposition:
• Novel resource for evaluating
disease etiology and biomarkers,
therapeutic evaluation, and improved
imaging strategies in epithelial ovarian
cancer
• Similarity to human ovarian cancer
based on transcriptional profiling
• Suitable preclinical cancer models
with high predictive value.
Development Stage: Pre-clinical (in
vivo validation).
Inventor(s): Simone Difilippantonio,
Terry Van Dyke, Zoe Weaver Ohler,
Ludmila Szabova, Sujata Bupp, Yurong
Song, Chaoying Yin.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
48439
Intellectual Property: Research use—
no patent protection will be sought.
Publications:
1. Szabova L., Yin C., Bupp S., et al.
Perturbation of Rb, p53 and Brca1
or Brca2 cooperate in inducing
metastatic serous epithelial ovarian
cancer. Cancer research.
2012;72(16):4141–4153.
2. Szabova L., Bupp S., Kamal M., et al.
Pathway-Specific Engineered
Mouse Allograft Models
Functionally Recapitulate Human
Serous Epithelial Ovarian Cancer.
Katoh M., ed. PLoS ONE.
2014;9(4):e95649.
Collaboration Opportunity:
Researchers at the NCI seek licensing
and/or co-development research
collaborations for the commercialization
of agents for the treatment of SEOC.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: July 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–17419 Filed 7–22–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Pediatric Heart Network Clinical Research
Centers (UG1).
Date: August 17–18, 2016
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 81, Number 142 (Monday, July 25, 2016)]
[Notices]
[Page 48439]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD, 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Novel metastatic serous epithelial ovarian
cancer (SEOC) genetically engineered mouse models, cell lines, and
orthotopic models based on Rb, p53 and/or Brca 1/2 inactivation useful
for biomarker discovery and preclinical testing.
Description of Technology: The high mortality rate from ovarian
cancers can be attributed to late-stage diagnosis and lack of effective
treatment. Despite enormous effort to develop better targeted
therapies, platinum-based chemotherapy still remains the standard of
care for ovarian cancer patients, and resistance occurs at a high rate.
One of the rate limiting factors for translation of new drug
discoveries into clinical treatments has been the lack of suitable
preclinical cancer models with high predictive value.
NCI CAPR has developed Tri-allelic K18-T121 tg/+ /Brca1
fl/fl /p53 fl/fl SEOC GEM Model, GEM-derived SEOC
orthotopic mouse model, and biological materials derived therefrom,
with several key histopathologic, immunophenotypical, and genetic
features of human SEOC. SEOC GEMs were utilized to create orthotopic
immunocompetent transplant models, and to generate synchronized cohorts
of mice suitable for preclinical studies. NCI CAPR conducted studies
that determine these models are tractable for use in routine efficacy
studies and demonstrate the utility of these models in evaluating the
potential efficacy of novel therapeutics for ovarian cancer.
Potential Commercial Applications:
These models serve as a foundation for preclinical
research and evaluation of efficacy of novel therapeutics for ovarian
cancer.
The GEM models described here can be used to develop cell
lines and allograft models for evaluating drug potency relative to
Brca1 mutation status.
These mouse models provide the opportunity for evaluation
of effective therapeutics, including prediction of differential
responses in Brca1-wild type and Brca1-deficient tumors and development
of relevant biomarkers.
Value Proposition:
Novel resource for evaluating disease etiology and
biomarkers, therapeutic evaluation, and improved imaging strategies in
epithelial ovarian cancer
Similarity to human ovarian cancer based on
transcriptional profiling
Suitable preclinical cancer models with high predictive
value.
Development Stage: Pre-clinical (in vivo validation).
Inventor(s): Simone Difilippantonio, Terry Van Dyke, Zoe Weaver
Ohler, Ludmila Szabova, Sujata Bupp, Yurong Song, Chaoying Yin.
Intellectual Property: Research use--no patent protection will be
sought.
Publications:
1. Szabova L., Yin C., Bupp S., et al. Perturbation of Rb, p53 and
Brca1 or Brca2 cooperate in inducing metastatic serous epithelial
ovarian cancer. Cancer research. 2012;72(16):4141-4153.
2. Szabova L., Bupp S., Kamal M., et al. Pathway-Specific Engineered
Mouse Allograft Models Functionally Recapitulate Human Serous
Epithelial Ovarian Cancer. Katoh M., ed. PLoS ONE. 2014;9(4):e95649.
Collaboration Opportunity: Researchers at the NCI seek licensing
and/or co-development research collaborations for the commercialization
of agents for the treatment of SEOC.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: July 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-17419 Filed 7-22-16; 8:45 am]
BILLING CODE 4140-01-P
